Company LianBio

Equities

LIAN.Y

US53000N1081

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - OTC Markets Other stock markets 12:14:03 2024-05-03 EDT			5-day change	1st Jan Change
0.305 ^USD	-2.89%		+8.62%	-93.18%

03-18	LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index	CI
03-15	ADRs End Lower; Akso Health Group Declines 23%	DJ

LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.

Number of employees: 163

Managers	Title	Age	Since
Adam Stone CEO	Chief Executive Officer	44	19-09-30
Levvy Lv PRN	Corporate Officer/Principal	42	20-03-31
Nathan Chen LAW	General Counsel	56	20-01-31
Pascal Qian PRN	Corporate Officer/Principal	56	21-06-30
Brianne Jahn PRN	Corporate Officer/Principal	38	20-01-31
Michael Humphries PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Tassos Gianakakos BRD	Director/Board Member	51	20-07-31
Adam Stone CEO	Chief Executive Officer	44	19-09-30
Wei Wei Chen BRD	Director/Board Member	58	22-04-06
Konstantin Poukalov FOU	Founder	40	19-07-16
Neil Kumar BRD	Director/Board Member	45	19-09-30
Susan Silbermann BRD	Director/Board Member	61	21-10-11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	107,168,686	43,735,541 ( 40.81 %)	0	40.81 %

Name	Equities	%	Valuation
Perceptive Advisors LLC 53.26 %	57,558,451	53.26 %	19 M $
Perceptive Advisors LLC 53.26 %	57,558,451	53.26 %	19 M $
Tang Capital Management LLC 8.668 %	9,366,783	8.668 %	3 M $
Affinity Asset Advisors LLC 3.498 %	3,779,694	3.498 %	1 M $
Viking Global Investors LP 3.298 %	3,564,173	3.298 %	1 M $
Tybourne Capital Management (HK) Ltd. 3.145 %	3,398,890	3.145 %	1 M $
22NW LP 2.047 %	2,211,678	2.047 %	714 372 $
BlackRock Advisors LLC 1.107 %	1,195,716	1.107 %	386 216 $
SCHF (GPE) LLC 0.8676 %	937,500	0.8676 %	302 813 $
Renaissance Technologies LLC 0.3202 %	346,000	0.3202 %	111 758 $

Name	Equities	%	Valuation
BRIDGEBIO PHARMA, INC. 4.753 %	5,002,792	4.753 %	2 M $
Debra Yu 0.9501 %	1,000,000	0.9501 %	323 000 $
Tassos Gianakakos 0.3451 %	363,253	0.3451 %	117 331 $
Jiang Qian 0.2768 %	291,354	0.2768 %	94 107 $
Brianne Jahn 0.2128 %	224,005	0.2128 %	72 354 $
Adam Stone 0.0162 %	17,082	0.0162 %	5 517 $
Susan Silbermann 0.0162 %	17,082	0.0162 %	5 517 $
Konstantin Poukalov 0.0162 %	17,082	0.0162 %	5 517 $
Ehong Gu 0.000000 %	0	0.000000 %	- $
Yi Zhe Wang 0.000000 %	0	0.000000 %	- $

LianBio

103 Carnegie Center Drive Suite 309

08540, Princeton

http://www.lianbio.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
LIANBIO	-93.18%	33.21M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B
VIKING THERAPEUTICS, INC.	+313.59%	8.49B

Bio Therapeutic Drugs